Taurine deficiency after intensive chemotherapy and/or radiation

Am J Clin Nutr. 1992 Mar;55(3):708-11. doi: 10.1093/ajcn/55.3.708.

Abstract

Taurine, a nonessential amino acid (AA), is the most abundant free AA in the intracellular space. We measured plasma AA concentrations in 36 patients 7-28 d after intensive chemotherapy and/or radiation. Plasma taurine concentrations were uniformly low in all patients (20.0 +/- 6.4 mumol/L, mean +/- SD). Plasma taurine in 11 healthy volunteer control subjects was 45.0 +/- 20.3 mumol/L (P less than 0.001). Other AA concentrations, specifically those of precursor AAs methionine and cystine, were normal. We prospectively measured plasma AA concentrations in 12 patients before starting and 6-10 d after completing intensive cytotoxic treatment. Values before treatment were 37.2 +/- 11.6, 109.6 +/- 30.7, and 18.5 +/- 4.8 for taurine, cystine, and methionine, respectively, and were 24.3 +/- 6.0, 111.2 +/- 23.8, and 24.0 +/- 14.5 after treatment. Pretreatment plasma taurine correlated directly with the magnitude of decrease in plasma taurine during cytotoxic treatment (n = 12, r = 0.85, P less than 0.01). Intensive cytotoxic chemotherapy and/or radiation leads to a reduction in plasma taurine concentrations without any change in its precursor AAs, methionine and cystine. The clinical relevance of plasma taurine depletion will need further study.

MeSH terms

  • Adolescent
  • Adult
  • Anemia, Aplastic / therapy
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Leukemia / therapy
  • Lymphoma / therapy
  • Male
  • Neuroblastoma / therapy
  • Radiotherapy / adverse effects*
  • Taurine / blood
  • Taurine / deficiency*
  • Taurine / urine

Substances

  • Antineoplastic Agents
  • Taurine